Literature DB >> 2412434

Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors.

A M Gown, A M Vogel.   

Abstract

A panel of monoclonal antibodies to human intermediate filament proteins was tested on an unselected series of 246 neoplasms. The antibody panel includes two different anti-cytokeratin antibodies, an anti-vimentin antibody, and an anti-neurofilament antibody (Gown and Vogel, Am J Pathol 114:309, 1984). The studies were done on Carnoy's or methacarn-fixed, paraffin-embedded tissue. When used as a panel, they can unequivocally distinguish carcinomas, melanomas, and lymphomas. All carcinomas react with at least one of the anti-cytokeratin antibodies, and carcinomas can be subtyped based upon the pattern of reactivity with the two anti-cytokeratin antibodies. Melanomas react only with the anti-vimentin antibody, and lymphomas react with none of the antibodies. Neural and neuroendocrine tumors can be identified with the anti-neurofilament antibody. A minority of neoplasms, including lymphomas, seminomas, and some sarcomas, do not react with any of the antibodies. These antibodies are reliable diagnostic reagents that are useful in distinguishing different categories of human tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412434     DOI: 10.1093/ajcp/84.4.413

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  32 in total

1.  Carcinocythemia. A terminal manifestation of metastatic breast cancer.

Authors:  D M Aboulafia
Journal:  West J Med       Date:  1992-12

2.  Anti-vimentin antibody reactivity with Reed-Sternberg cells of Hodgkin's disease.

Authors:  A Carbone; A Gloghini; R Volpe; M Boiocchi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

3.  Intermediate-filament expression in thyroid gland carcinomas.

Authors:  S Schröder; B Dockhorn-Dworniczak; H Kastendieck; W Böcker; W W Franke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Intermediate filament expression in carcinoid tumours.

Authors:  E E Mooney; M Casey; P A Dervan
Journal:  Ir J Med Sci       Date:  1991-11       Impact factor: 1.568

5.  Pathology: immunohistochemistry and the diagnosis of spindle cell neoplasms.

Authors:  D R Chase
Journal:  West J Med       Date:  1986-09

6.  Detection of keratin subtypes in routinely processed cervical tissue: implications for tumour classification and the study of cervix cancer aetiology.

Authors:  F Smedts; F Ramaekers; M Link; L Lauerova; S Troyanovsky; C Schijf; G P Vooijs
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines.

Authors:  R Moll; T Achtstätter; E Becht; J Balcarova-Ständer; M Ittensohn; W W Franke
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

8.  Biochemical evidence that cytokeratins are present in smooth muscle.

Authors:  H Turley; K A Pulford; K C Gatter; D Y Mason
Journal:  Br J Exp Pathol       Date:  1988-06

Review 9.  Clear cell carcinoma of the breast with solid papillary pattern: a case report with immunohistochemical profile.

Authors:  Y Gürbüz; S K Ozkara
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

10.  Expression of secreted frizzled-related protein 2 in a primary canine mammary tumor cell line: a candidate tumor marker for mammary tumor cells.

Authors:  Jia-Lin Lee; Ching-Jin Chang; Ling-Ling Chueh; Chung-Tien Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 May-Jun       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.